Shares of Ligand Pharmaceuticals Incorporated (LGND) are moving up about 7 percent on Tuesday morning trading after its partner Travere Therapeutics, Inc. received approval from the U.S. Food and Drug Administration for FILSPARI to reduce proteinuria.
The company's shares are currently trading at $230.32 on the Nasdaq, up 7.87 percent. The stock opened at $220.00 and has climbed as high as $230.51 so far in today's session. Over the past year, it has traded in a range of $98.89 to $230.51.
The approval comes as Travere's Phase 3 DUPLEX Study, the largest head-to-head interventional study in FSGS to date, showed that patients treated with FILSPARI in the overall study population experienced a statistically significant 46% reduction in proteinuria from baseline to Week 108 compared to 30% for those treated with maximum labeled dose irbesartan.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.